ARTICLE | Company News
AbbVie buys United's Priority Review voucher
August 20, 2015 2:35 AM UTC
United Therapeutics Corp. (NASDAQ:UTHR) said it sold a rare pediatric disease Priority Review voucher to AbbVie Inc. (NYSE:ABBV) for $350 million. AbbVie spokesperson Adelle Infante declined to disclose the company's plans for the voucher.
United received the voucher in March when FDA approved Unituxin dinutuximab to treat high-risk pediatric neuroblastoma (see BioCentury Extra, March 10). ...